It is a long-term collaboration, it is profitable, it could lead to new products and it is a fast-growing business area, says Dako-CEO Lars Holmkvist about a recent collaboration agreement between the Danish company and the world’s largest pharmaceutical group, Pfizer.
“It is a collaboration that will run for several years and it is a wide-reaching agreement, through which Pfizer and Dako will work together on several aspects that have the potential to lead to new diagnostic products in our portfolio,” the CEO tells Medwatch and adds:
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app